With the development of the Internet, innovation in the field of medical services has grown tremendously. Although this has increased the fragmentation of the original fragmented service system, it has also seen the market see some hope, especially with the innovation of offline medical services. Compared to slow development, online innovation has received unprecedented attention. However, it is not easy for innovation to gain market recognition. Especially in the field of medical services, innovation must conform to the intrinsic value and external boundaries of medical services.
Medical services are a very trivial and meticulous job, and with the payment and supervision of third-party payers, medical services are in fact around standards and have clear boundaries. The entire medical service runs with a complete set of standards. All transactions are carried out around standards. Any innovation that attempts to circumvent this set of standards cannot be implemented. This is no doubt equal to leaving your hair off the ground. If you really want to circumvent the current standards, it is to jump out of the boundaries of the system to create a new set of medical services standards, but for the light service operations of medical services companies is simply not possible.
Therefore, innovation in the field of medical services has a large bottleneck, and many seemingly beautiful models cannot avoid real problems. In essence, the slow progress of offline medical service innovation is for a reason, not a technical means or a business model can be easily changed. The standard defines the boundaries for all medical services. Innovation is inevitable to cross the border, but as the analysis above, cross-border boundaries must be supported by their own new standards, as well as their own new regional medical service network. Without the support of the system of payments and services, any so-called innovation will fail. For example, the high-end medical services developed in the past 10 years have been supported by high-end medical insurance. And high-end medical insurance is clearly with a set of its own payment standards to cooperate with medical services, although this standard is actually very fragile, can not help the payer to constrain the service side, but after all, such a set of standards still supports a small market .
Plant growth regulators are organic compounds that are artificially synthesized (or natural extracted from microorganisms) and have growth and development regulation similar to natural plant hormones. Insen Biotech is specilized in Plant Growth Stimulants with large capacity and competitive price, including 1-naphthylacetic acid, Indole acetic acid(IAA), Indole butyric acid(IBA), Triacontanol, Diethyl aminoethyl hexanoate(Da-6), Brassinolide, 6-benzyladenine(6-BA), Forchlorfenuron(CPPU), Gibberellin acid(GA3).
Plant Growth Regulator,Indol Butyric Acid,Plant Growth Stimulant,Indole Butyric Acid
Hunan Insen Biotech Co., Ltd , https://www.insenhealth.com